|Bid||195.64 x 900|
|Ask||196.36 x 800|
|Day's Range||194.41 - 196.38|
|52 Week Range||116.08 - 207.17|
|Beta (5Y Monthly)||0.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 26, 2023 - Jul 31, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||222.64|
Subscribe to Yahoo Finance Plus to view Fair Value for SGENLearn more
BOTHELL, Wash., May 30, 2023--Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash. More than 99% of the shares voted at the meeting, representing approximately 88% of the shares of Seagen common stock issued and outstanding as of the record date for the special meeting, were voted in favor of
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
The regulator said its decision "sends a clear signal to the market" about consolidation in the pharmaceutical market, though analysts expect the deal will still go through despite delays.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Key Insights Significantly high institutional ownership implies Seagen's stock price is sensitive to their trading...
Key Insights Using the 2 Stage Free Cash Flow to Equity, Seagen fair value estimate is US$193 With US$200 share price...
Looking at Seagen Inc.'s ( NASDAQ:SGEN ) insider transactions over the last year, we can see that insiders were net...
While the top- and bottom-line numbers for Seattle Genetics (SGEN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.41% and 0.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BOTHELL, Wash., April 27, 2023--Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023. The Company also highlighted performance across its approved product portfolio, development accomplishments, and progress across its differentiated oncology pipeline of innovative ADCs and targeted therapies.
BOTHELL, Wash., April 26, 2023--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, in Chicago. Data will be presented across Seagen's portfolio of approved medicines and pipeline agents in a range of cancer types and in earlier lines of therapy.
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
You may think that with a price-to-sales (or "P/S") ratio of 19.6x Seagen Inc. ( NASDAQ:SGEN ) is a stock to avoid...
Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...
BOTHELL, Wash., April 07, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023.
BOTHELL, Wash. & TOKYO, April 03, 2023--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced the U.S. Food and Drug Administration (FDA) has granted PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) accelerated approval in the U.S. as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who are not eligible to receive cisplatin-containing chemotherapy. This indication is approved under ac
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viewing insider transactions for Seagen Inc.'s ( NASDAQ:SGEN ) over the last year, we see that insiders were net...
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street’s biggest banks swooped in to rescue First Republic after a week of turmoil. First Republic was among the banks swept up in the contagion following the recent failure of Silicon Valley Bank parent SVB Financial Corp. Banks including JPMorgan Chase & Co. Citigroup and Wells Fargo & Co., deposited a total of $30 billion in an effort to stop the spreading panic. First Republic shares dropped 33% Friday.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.